Mode
Text Size
Log in / Sign up
Phase 4 Completed N=54 Randomized Double-blind Treatment

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

Source: ClinicalTrials.gov NCT02657031 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcomePrimary: Headache Following Intervention — 63.5; 43.5 mm
◆ Published Evidence
Highly cited
558citations · ~31 / year
National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary.
National health statistics reports · 2008 · High-confidence link

Summary

This study compares the efficacy of low dose Ketamine versus Compazine for the control of headache in patients presenting to the Emergency Department.

Linked Publications (5)

  • National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary.
    National health statistics reports · 2008 · 558 citations · High-confidence link
  • A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room.
    The Neurohospitalist · 2012 · 101 citations · High-confidence link
  • A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
    Annals of emergency medicine · 2010 · 75 citations · High-confidence link
  • Prospective, randomised, double blind, controlled comparison of metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension type headache episodes.
    Emergency medicine journal : EMJ · 2004 · 67 citations · Open access · High-confidence link
  • A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
    Annals of emergency medicine · 2013 · 41 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Headache Following Intervention
63.5; 43.5
SECONDARY
Anxiety
33.7; 21.2
SECONDARY
Nausea
38.9; 22.9
SECONDARY
The Number of Participants Experiencing Vomiting
2; 3
SECONDARY
The Number of Patients Experiencing Restlessness
3; 3

Eligibility Criteria

Inclusion Criteria

  • Age 18 to 65 years
  • Temperature < 100.4° F
  • Diastolic Blood Pressure <104 mm Hg
  • Normal neurological exam and mormal mental status

Exclusion Criteria

  • Pregnant or breastfeeding.
  • Meningeal signs are present
  • Acute angle closure glaucoma is suspected.
  • Head trauma within the previous two weeks
  • Lumbar puncture within the previous two weeks
  • Thunderclap onset of the headache
  • Weight more than 150 kg or less than 40 kg.
  • Known allergy to one of the study drugs.
  • History of schizophrenia or bipolar disorder.
  • History of intracranial hypertension.
  • Is a prisoner
  • Patient declined informed consent
  • Non-English speaking patient.
  • Attending provider excludes patient
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02657031) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search